NCT04060277View on ClinicalTrials.gov

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 27, 2019

Primary Completion Date

June 6, 2023

Study Completion Date

April 7, 2030

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmHodgkin LymphomaLymphoblastic LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmNon-Hodgkin Lymphoma
Interventions
DRUG

Letermovir

Given as SOC

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

OTHER

Placebo Administration

Given IM

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT04060277 - Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter